Informed Prostate Cancer Patient Support

Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine

Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based on 18F-Fluciclovine PET/CT Guidance | Journal of Nuclear Medicine

Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases | Journal of Nuclear Medicine

Synthesis and Evaluation of 18F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-18F-Fluoro-5α-Dihydrotestosterone | Journal of Nuclear Medicine

Matched-Pair Comparison of 68Ga-PSMA-11 and 18F-rhPSMA-7 PET/CT in Patients with Primary and Biochemical Recurrence of Prostate Cancer: Frequency of Non–Tumor-Related Uptake and Tumor Positivity | Journal of Nuclear Medicine

Neuropathy and Light Therapy - The Health Science Journal

Patient-specific Boolean models of signaling networks guide personalized treatments | bioRxiv

Healthy lifestyle may offset risk of lethal prostate cancer in men with high genetic risk - YouTube

Bone Drugs for Prostate Cancer May Result in Survival Benefit

Assessment of the optimal number of positive biopsy cores to discriminate between cancer‐specific mortality in high‐risk versus very high‐risk prostate cancer patients - Wenzel - - The Prostate - Wiley Online Library

The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy - Prebay - - The Prostate - Wiley Online Library

Early PSA kinetics for low- and intermediate-risk prostate cancer treated with definitive radiation therapy - ScienceDirect

Combination Therapy Shows Promise in Prostate Cancer

Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative | Prostate Cancer and Prostatic Diseases

Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort - Lonergan - - The Prostate - Wiley Online Library

Lack of After Care Leaves Cancer Patients in 'Survivorship Abyss'

Common Advanced Prostate Cancer Treatments Not Tied to Significant Cognitive Decline

Hitting a Nerve: Introduction to Neuropathy – Diabetes Daily

Adding MRI to Screening Can Cut Prostate Cancer Over Diagnosis in Half | Cooking with Kathy Man cookwithkathy.wordpress.com Adding MRI to Screening Can Cut Prostate Cancer Over Diagnosis in Half Ernie Mundell and Robert Preidt wrote . . . . . . . . . One of the big issues in prostate cancer care is over diagnosis — men who are treated for low-risk, slow-growing tumors that might be better left monitored and untreated. Now, research out of Sweden suggests that having patients undergo MRI screening, along with targeted biopsies, could reduce the number of prostate cancer over diagnoses by half. The new approach can detect just as many clinically significant tumors as current methods, but reduces unnecessary biopsies and the identification of minor low-risk tumors, according to the study presented recently at the European Association of Urology Congress. The findings were published simultaneously in the New England Journal

Probiotics {July 2021} Why Men Need Them Too

Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: results of a multicenter trial with 30 days’ follow-up | Prostate Cancer and Prostatic Diseases

The microbiome and prostate cancer | Prostate Cancer and Prostatic Diseases

Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study | Prostate Cancer and Prostatic Diseases

Can exercise prevent the onset of chemotherapy-induced peripheral neuropathy? | British Journal of Cancer

Integrated digital pathology at scale: A solution for clinical diagnostics and cancer research at a large academic medical center | Journal of the American Medical Informatics Association | Oxford Academic

The Role of Neurotropic B Vitamins in Nerve Regeneration Damage and regeneration naturally occur in the peripheral nervous system. The neurotropic B vitamins thiamine (B1), pyridoxine (B6), and cobalamin (B12) are key players, which maintain the neuronal viability in different ways. Firstly, they constantly protect nerves against damaging environmental influences. While vitamin B1 acts as a site-directed antioxidant, vitamin B6 balances nerve metabolism, and vitamin B12 maintains myelin sheaths. However, nerve injury occurs at times, because of an imbalance between protective factors and accumulating stress and noxae. This will result in the so-called Wallerian degeneration process.  The presence of vitamins B1, B6, and B12 paves the way out to the following important regeneration by supporting the development of new cell structures. Furthermore, vitamin B1 facilitates the usage of carbohydrates for energy production, whereas vitamin B12 promotes nerve cell survival and re

The Costs of Delayed Generic Drug Entry: Evidence from a Controversial Prostate Cancer Drug Patent | SpringerLink

Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound‐guided prostate biopsy - Liu - - The Prostate - Wiley Online Library

Observed evidence for guideline‐recommended genes in predicting prostate cancer risk from a large population‐based cohort - Wei - - The Prostate - Wiley Online Library

Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience - Wee - - The Prostate - Wiley Online Library

Reclassification prediction of first-year protocol biopsy on active surveillance of prostate cancer by p2PSA-related parameters: from PRIAS-JAPAN | Prostate Cancer and Prostatic Diseases

A patient-driven clinicogenomic partnership through the Metastatic Prostate Cancer Project | bioRxiv

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening | NEJM

New concept drug hunts down late-stage prostate cancer | EurekAlert! Science News eurekalert.org New concept drug Lu-PSMA-617 hunts down late-stage prostate cancer 4-5 minutes A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today. Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment. Profes

MRI-Targeted or Standard Biopsy in Prostate Cancer Screening | NEJM nejm.org MRI-Targeted or Standard Biopsy in Prostate Cancer Screening Tobias Nordström 42-53 minutes 33 References Abstract Background High rates of overdiagnosis are a critical barrier to organized prostate cancer screening. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address this challenge, but the implications of its use in the context of organized prostate cancer screening are unknown. Methods We conducted a population-based noninferiority trial of prostate cancer screening in which men 50 to 74 years of age from the general population were invited by mail to participate; participants with prostate-specific antigen (PSA) levels of 3 ng per milliliter or higher were randomly assigned, in a 2:3 ratio, to undergo a standard biopsy (standard biopsy group) or to undergo MRI, with targeted and s

  medpagetoday.com Support for MRI-Targeted Biopsy in Prostate Cancer Screening by Mike Bassett, Staff Writer, MedPage Today July 9, 2021 5-7 minutes Meeting Coverage > Additional Meetings — Large Swedish study showed the approach cut overdiagnosis, unnecessary biopsies A prostate cancer screening strategy using MRI with targeted and standard biopsy reduced the detection of clinically insignificant cancers as well as unnecessary biopsies, researchers reported. Such an approach was also as effective as a standard biopsy strategy in detecting clinically significant cancers, said Tobias Nordstrom, MD, PhD, of the Karolinska Institutet in Stockholm, in a presentation at the virtual European Association of Urology Congress. The results were publish

AI tool analyzes CT scans to spot prostate cancer in seconds newatlas.com AI tool analyzes CT scans to spot prostate cancer in seconds By Nick Lavars 3-4 minutes Continuous advances in artificial intelligence promise to shake up medical care in all kinds of exciting ways, with the ability to rapidly scan medical images and spot signs of disease far more efficiently than humans can. Scientists in Australia have now adapted this technology for the early detection of prostate cancer, with their software outperforming trained radiologists to detect cancerous growths in seconds. For many medical ailments, an early diagnosis can greatly improve the treatments available and therefore the chances of overcoming them. Improvements in machine learning and computing power have led to highly capable forms of artificial intelligence that could be invaluable in this regard. We've seen AI tools t

MRI Plus New Score Halves Biopsy Rate for Prostate Cancer medscape.com MRI Plus New Score Halves Biopsy Rate for Prostate Cancer Neil Osterweil 3-4 minutes More good tidings to gladden the hearts of men who have reached the half century mark: Swapping traditional prostate biopsies for MRI-targeted biopsies with a new prostate cancer risk score can cut the number of unnecessary biopsies in half while still detecting clinically significant cancers. The findings from the STHLM3MRI study , a large randomized trial, were published online in The New England Journal of Medicine to coincide with a presentation of the results at European Association of Urology 2021 Annual Meeting (EAU 2021). The trial included nearly 2300 men with elevated prostate-specific antigen (PSA) levels and/or high scores on the Stockholm 3 predictive test . They were randomly assigned to undergo either systematic biopsy or

Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard | Journal of Nuclear Medicine jnm.snmjournals.org Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard Maythinee Chantadisai 4 minutes Research Article Theranostics , Gabriel Buschner , Markus Krönke , Isabel Rauscher , Thomas Langbein , Stephan G. Nekolla , Kilian Schiller , Matthias M. Heck , Tobias Maurer , Alexander Wurzer , Hans-Juergen Wester , Calogero D’Alessandria , Wolfgang Weber and Matthias Eiber Journal of Nuclear Medicine July 2021, 62 (7) 968-974; DOI: https://doi.org/10.2967/jnumed.120.255661 Abstrac

Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging | Journal of Nuclear Medicine jnm.snmjournals.org Biochemical Persistence of Prostate-Specific Antigen After Robot-Assisted Laparoscopic Radical Prostatectomy: Tumor Localizations Using PSMA PET/CT Imaging Dennie Meijer 3-4 minutes Research Article Theranostics , Maarten L. Donswijk , Yves J.L. Bodar , Pim J. van Leeuwen , Henk G. van der Poel , Wouter V. Vogel , Jakko A. Nieuwenhuijzen , N. Harry Hendrikse , Daniela E. Oprea-Lager and André N. Vis Journal of Nuclear Medicine July 2021, 62 (7) 961-967; DOI: https://doi.org/10.2967/jnumed.120.252528 Abstract Since the introduction of radiolabeled prostate-specific membra

Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis | Prostate Cancer and Prostatic Diseases nature.com Progression on active surveillance for prostate cancer in Black men: a systematic review and meta-analysis Michael R. Abern 20-25 minutes Abstract Background Several studies evaluated prostate cancer (PCa) outcomes in Black men on active surveillance (AS); most studies contained few Black men and results were conflicting. We performed a systematic review and meta-analyze of race and outcomes on AS. Methods A systematic search was performed for articles of men with Grade Group 1 or 2 (GG1 or GG2) PCa on AS. All studies required race-specific comparative progression data. Progression to treatment, PSA, or biopsy progression were considered and relative risk (RR) estimates of